Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q2 2011

Published by: Global Markets Direct

Published: Apr. 30, 2011 - 47 Pages


Table of Contents

Introduction
Introduction
Global Markets Direct Report Coverage
Systemic Juvenile Idiopathic Arthritis (SJIA) Overview
Therapeutics Development
An Overview of Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA)
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Development by Companies
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Products under Development by Companies
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Development
F. Hoffmann-La Roche Ltd.
Novartis AG
Protalix BioTherapeutics, Inc.
XOMA Ltd.
Italfarmaco S.p.A.
Systemic Juvenile Idiopathic Arthritis (SJIA) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACZ885 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actemra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Product Description
Mechanism of Action
R&D Progress
XOMA 052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anakinra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infliximab + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rilonacept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Givinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Drug Profile Updates
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Discontinued Products
Systemic Juvenile Idiopathic Arthritis (SJIA) - Featured News
Oct 18, 2010: Roche Submits ACTEMRA/RoACTEMRA Supplemental Marketing Authorizations In US And Europe For Treatment Of Systemic Juvenile Idiopathic Arthritis
Jun 15, 2010: TxCell Successfully Completes Preclinical Development of TX-RAD in Inflammatory Arthritis
Nov 20, 2009: Roche Announces Phase III Clinical Study Results Of ACTEMRA In Children With Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), Q2 2011
Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
F. Hoffmann-La Roche Ltd., 2011
Novartis AG, 2011
Protalix BioTherapeutics, Inc., 2011
XOMA Ltd., 2011
Italfarmaco S.p.A., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), Q2 2011
Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Abstract

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q2 2011', provides an overview of the Systemic Juvenile Idiopathic Arthritis (SJIA) therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA). 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis (SJIA).
  • A review of the Systemic Juvenile Idiopathic Arthritis (SJIA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Systemic Juvenile Idiopathic Arthritis (SJIA).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline depth and focus of Systemic Juvenile Idiopathic Arthritis (SJIA) therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.